Evidence map›Paper›PMID 31177329›Full record

ArticleCancer immunology, immunotherapy : CII2019

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.

Wenjie Gong, Jean-Marc Hoffmann, Sophia Stock, Lei Wang, Yibin Liu, Maria-Luisa Schubert, Brigitte Neuber, Angela Hückelhoven-Krauss, Ulrike Gern, Anita Schmitt and 4 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 51 citations in OpenAlex.

  1. Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Wenjie GongCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-6965-6209
Jean-Marc HoffmannCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Sophia StockCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Lei WangCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Yibin LiuCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Maria-Luisa SchubertCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Brigitte NeuberCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Angela Hückelhoven-KraussCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Ulrike GernCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Anita SchmittCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Carsten Müller-TidowCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Hiroshi ShikuDepartment of Immuno-Gene Therapy, Mie University, Tsu, Japan.
Michael SchmittCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Leopold SellnerCellular Immunotherapy Unit, Department of Internal Medicine V, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. lsellner.hd@gmail.com.
Heidelberg University · DEMie University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-tumor efficacy of TCR-engineered T cells in vivo depends largely on less-differentiated subsets such as T cells with naïve-like T cell (T

Indexed as

Antigens, CD19Antigens, NeoplasmCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Culture TechniquesCell EngineeringCell Line, TumorCulture MediaHumansImmunotherapy, AdoptiveInterleukin-15Interleukin-2Interleukin-7Membrane ProteinsNeoplasmsReceptors, Chimeric AntigenAntigens, CD19Antigens, NeoplasmCD19 molecule, humanCTAG1B protein, humanCulture MediaIL15 protein, humanIL2 protein, humanIL7 protein, humanInterleukin-15Interleukin-2Interleukin-7Membrane ProteinsReceptors, Chimeric AntigenAdoptive T cell transferInterleukinNY-ESO-1T cell receptor

Identifiers

PMID31177329
PMCPMC11028180
OpenAlexW2950835482

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.